{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:51:26Z","timestamp":1763542286799,"version":"3.45.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess whether Steroid-Refractory chronic Graft-versus-Host Disease (SR-cGvHD) patients with oral involvement benefit from ruxolitinib regarding their clinical symptoms and oral lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A prospective real-life observational longitudinal patient study was conducted in patients with SR-cGVHD and oral involvement who were treated with ruxolitinib. The effects of ruxolitinib on oral lesions and symptoms were assessed 12 weeks after the start of treatment with ruxolitinib based on the complete response, partial response, and overall response rate. Additionally, oral mucosal clinical characteristics and symptoms were assessed using validated outcome scales 4 and 12 weeks after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 17 patients was included. Overall response rate after 12 weeks was 77%: 12% had a complete response and 65% had a partial response. A significant decrease was seen in presence of erythema (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), lichenoid lesions (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), median lesion site score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and activity score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) after 12 weeks. Discomfort experienced by the patients in terms of mouth dryness, mouth pain, and mouth sensitivity was significantly ameliorated (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of oral SR-cGVHD with ruxolitinib ameliorates oral lesions and symptoms experienced by patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance<\/jats:title>\n                    <jats:p>: Ruxolitinib effectively treats symptoms of oral cGHVD as shown by real world evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00784-025-06604-x","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T02:13:12Z","timestamp":1762395192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of ruxolitinib on the oral mucosa in steroid-refractory graft-versus-host disease: a prospective observational exploratory study"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-5816","authenticated-orcid":false,"given":"Mar","family":"Bellido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7144-4192","authenticated-orcid":false,"given":"Ana-Mae E.","family":"Jonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-2955","authenticated-orcid":false,"given":"Martina","family":"Kaurinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouschka","family":"Biswana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-4668","authenticated-orcid":false,"given":"Carin L. E.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2348-5947","authenticated-orcid":false,"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-5298","authenticated-orcid":false,"given":"Linde M.","family":"Morsink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6789-6433","authenticated-orcid":false,"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2581-4361","authenticated-orcid":false,"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-3977","authenticated-orcid":false,"given":"Konstantina","family":"Delli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"6604_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1517\/14728214.2016.1170117","volume":"21","author":"N Kekre","year":"2016","unstructured":"Kekre N, Antin JH (2016) Emerging drugs for graft-versus-host disease. Expert Opin Emerg Drugs 21:209\u2013218. https:\/\/doi.org\/10.1517\/14728214.2016.1170117","journal-title":"Expert Opin Emerg Drugs"},{"issue":"7","key":"6604_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Grzegorz WB, de la C\u00e1mara R, Corbaciogl S (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 56(7):1651\u20131664. https:\/\/doi.org\/10.1038\/s41409-021-01227-8","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"6604_CR3","doi-asserted-by":"publisher","first-page":"7016","DOI":"10.1182\/blood-2023-177866","volume":"142","author":"S Corbacioglu","year":"2023","unstructured":"Corbacioglu S, Mooyaart J, Polge E, Boreland W, Lemaitre J, Peczynski C et al (2023) Graft-versus-host disease (GVHD) and steroid-refractory GVHD after allogeneic hematopoietic stem cell transplantation: a large real-world EBMT-based epidemiology and treatment pattern study. Blood 142(Suppl 1):7016. https:\/\/doi.org\/10.1182\/blood-2023-177866","journal-title":"Blood"},{"issue":"6","key":"6604_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1182\/blood.v98.6.1695","volume":"98","author":"D Przepiorka","year":"2001","unstructured":"Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khoury I, Champlin E (2001) Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 98(6):1695\u20131700. https:\/\/doi.org\/10.1182\/blood.v98.6.1695","journal-title":"Blood"},{"issue":"1","key":"6604_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12885-018-5045-7","volume":"18","author":"N Bubnoff","year":"2018","unstructured":"Bubnoff N, Ihorst G, Grishina O, R\u00f6thling N, Bertz H, Duyster J, Zeiser R (2018) Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD). BioMed Cent Cancer Cancer 18(1):132. https:\/\/doi.org\/10.1186\/s12885-018-5045-7","journal-title":"BioMed Cent Cancer Cancer"},{"key":"6604_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.humimm.2019.03.003","volume":"80","author":"W McManigle","year":"2019","unstructured":"McManigle W, Youssef A, Sarantopoulos S (2019) B cells in chronic graft-versus-host disease. Hum Immunol 80:393\u2013399. https:\/\/doi.org\/10.1016\/j.humimm.2019.03.003","journal-title":"Hum Immunol"},{"issue":"4","key":"6604_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/odi.12028","volume":"19","author":"JW Mays","year":"2013","unstructured":"Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW (2013) Oral chronic graft-versus-host-disease: current pathogenesis, therapy, and research. Oral Dis 19(4):327\u2013346. https:\/\/doi.org\/10.1111\/odi.12028","journal-title":"Oral Dis"},{"issue":"1","key":"6604_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","volume":"158","author":"FL Dignan","year":"2012","unstructured":"Dignan FL, Amrolia P, Clark A, Cornish J, Jackson G, Mahendra P, Potter MN (2012) Diagnosis and management of chronic graft-versus-host-disease. Br J Haematol 158(1):46\u201361. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09128.x","journal-title":"Br J Haematol"},{"issue":"4","key":"6604_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1054\/blre.2000.0137","volume":"14","author":"S Arai","year":"2000","unstructured":"Arai S, Vogelsang GB (2000) Management of graft-versus-host-disease. Blood Rev 14(4):190\u2013204. https:\/\/doi.org\/10.1054\/blre.2000.0137","journal-title":"Blood Rev"},{"issue":"8","key":"6604_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood.V76.8.1464.1464","volume":"76","author":"PJ Martin","year":"1990","unstructured":"Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR, Sanders JE (1990) A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76(8):1464\u20131472","journal-title":"Blood"},{"issue":"2","key":"6604_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","volume":"25","author":"B Modi","year":"2019","unstructured":"Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, Nakamura R (2019) Ruxolitinib as salvage therapy for chronic Graft-versus-Host disease. Biol Blood Marrow Transplant 25(2):265\u2013269. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.003","journal-title":"Biol Blood Marrow Transplant"},{"key":"6604_CR12","doi-asserted-by":"crossref","unstructured":"Niklander, S., Veas, L., Barrera, C., Fuentes, F., Chiappini, G., Marshall, M. (2017).Risk factors, hyposalivation and impact of xerostomia on oral health-related quality of life. Brazillian Oral Research, 31, e14. doi: 10.1590\/1807-3107BOR-2017.vol31.0014.","DOI":"10.1590\/1807-3107bor-2017.vol31.0014"},{"issue":"3","key":"6604_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.25376","volume":"94","author":"M Gonz\u00e1lez Vicent","year":"2019","unstructured":"Gonz\u00e1lez Vicent M, Molina B, Gonz\u00e1lez de Pablo J, Castillo A, D\u00edaz M\u00c1 (2019) Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: clinical and immunological results. Am J Hematol 94(3):319\u2013326. https:\/\/doi.org\/10.1002\/ajh.25376","journal-title":"Am J Hematol"},{"key":"6604_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/hon.2505","volume":"36","author":"G Lancman","year":"2018","unstructured":"Lancman G, Coltoff A, Steinberg A (2018) Ruxolitinib for steroid-refractory graft-versus-host disease: A case series. Hematol Oncol 36:611\u2013613. https:\/\/doi.org\/10.1002\/hon.2505","journal-title":"Hematol Oncol"},{"issue":"7","key":"6604_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41409-017-0081-5","volume":"53","author":"HJ Khoury","year":"2018","unstructured":"Khoury HJ, Langston AA, Kota VK, Wilkinson JA, Pusic I, Jillella A, DiPersio JF (2018) Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease. Bone Marrow Transplant 53(7):826\u2013831. https:\/\/doi.org\/10.1038\/s41409-017-0081-5","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"6604_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41409-017-0068-2","volume":"53","author":"AM Ferreira","year":"2018","unstructured":"Ferreira AM, Pontes da Silva CA, Pereira AD, Szor RS, Medeiros da Fonseca AR, Serpa MG, Arrais-Rodrigues C (2018) Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center. Bone Marrow Transplant 53(4):503\u2013506. https:\/\/doi.org\/10.1038\/s41409-017-0068-2","journal-title":"Bone Marrow Transplant"},{"key":"6604_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-017-0092-3","volume":"6","author":"MS Maldonado","year":"2017","unstructured":"Maldonado MS, Villanueva PR, Cortes-Monroy PB, Arias VJ, Donoso KS, Gonzalez PU, Perez-Sim\u00f3n JA (2017) Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory to both corticosteroids and extracorporeal photopheresis. Experimental Hematol Oncol 6:32. https:\/\/doi.org\/10.1186\/s40164-017-0092-3","journal-title":"Experimental Hematol Oncol"},{"issue":"5","key":"6604_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bjh.14679","volume":"181","author":"D Assouan","year":"2018","unstructured":"Assouan D, Lebon D, Charbonnier A, Royer B, Marolleau JP, Gruson B (2018) Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. Br J Haematol 181(5):687\u2013689. https:\/\/doi.org\/10.1111\/bjh.14679","journal-title":"Br J Haematol"},{"issue":"5","key":"6604_CR19","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/bjd.15593","volume":"177","author":"C Hurabielle","year":"2017","unstructured":"Hurabielle C, Sicre de Fontbrune F, Moins-Teisserenc H, Robin M, Jachiet M, Coman T, Bouaziz JD (2017) Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. Br J Dermatol 177(5):e206\u2013e208. https:\/\/doi.org\/10.1111\/bjd.15593","journal-title":"Br J Dermatol"},{"issue":"10","key":"6604_CR20","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062\u20132068. https:\/\/doi.org\/10.1038\/leu.2015.212","journal-title":"Leukemia"},{"issue":"5","key":"6604_CR21","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1007\/s00784-022-04393-1","volume":"36","author":"M Kaurinovic","year":"2022","unstructured":"Kaurinovic M, Delli K, Jonk AE, Biswana A, Hazenberg CLE, Choi G, Bellido M (2022) Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement. Clin Oral Invest 36(5):4209\u20134216. https:\/\/doi.org\/10.1007\/s00784-022-04393-1","journal-title":"Clin Oral Invest"},{"issue":"3","key":"6604_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Locatelli F (2021) Ruxolitinib for Glucocorticoid-Refractory chronic Graft-versus-Host disease. N Engl J Med 385(3):228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"N Engl J Med"},{"issue":"6","key":"6604_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","volume":"21","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, Pavletic S (2015) Measuring therapeutic response in chronic graft-versus-host-disease. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 response criteria working group report. Biol Blood Marrow Transplant 21(6):984\u2013999. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.025","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"6604_CR24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/j.1365-2133.2007.08106.x","volume":"157","author":"M Escudier","year":"2007","unstructured":"Escudier M, Ahmed N, Shirlaw P, Setterfield J, Tappuni A, Black MM, Challacombe SJ (2007) A scoring system for mucosal disease severity with special reference to oral lichen planus. Br J Dermatol 157(4):765\u2013770. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08106.x","journal-title":"Br J Dermatol"},{"issue":"27","key":"6604_CR25","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1200\/JCO.2007.10.8456","volume":"25","author":"DA Jacobsohn","year":"2007","unstructured":"Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bola\u00f1os-Meade J, Vogelsang GB (2007) Phase II study of Pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 25(27):4255\u20134561. https:\/\/doi.org\/10.1200\/JCO.2007.10.8456","journal-title":"J Clin Oncol"},{"issue":"3","key":"6604_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Flowers MED (2015) National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease. Biol Blood Marrow Transplant 21(3):389\u2013401. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6604_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbmt.2006.01.008","volume":"12","author":"SZ Pavletic","year":"2006","unstructured":"Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Vogelsang GB (2006) Measuring therapeutic response in chronic graft-versus-host disease: National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-. chronic Graft-versus-Host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 12(3):252\u2013266. https:\/\/doi.org\/10.1016\/j.bbmt.2006.01.008","journal-title":"Biol Blood Marrow Transplant"},{"key":"6604_CR28","doi-asserted-by":"publisher","first-page":"e954268","DOI":"10.3389\/fimmu.2022.954268","volume":"13","author":"S Fan","year":"2022","unstructured":"Fan S, Huo WX, Yang Y, Shen MZ, Mo XD (2022) Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis. Front Immunol 13:e954268. https:\/\/doi.org\/10.3389\/fimmu.2022.954268","journal-title":"Front Immunol"},{"issue":"22","key":"6604_CR29","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","volume":"2","author":"C Cutler","year":"2002","unstructured":"Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A et al (2002) Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the rockstar study. Blood 2(22):2278\u20132289. https:\/\/doi.org\/10.1182\/blood.2021012021","journal-title":"Blood"},{"issue":"21","key":"6604_CR30","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I et al (2017) Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130(21):2243\u20132250. https:\/\/doi.org\/10.1182\/blood-2017-07-793786","journal-title":"Blood"},{"issue":"5","key":"6604_CR31","doi-asserted-by":"publisher","first-page":"e14255","DOI":"10.1111\/ctr.14255","volume":"35","author":"I Parra Salinas","year":"2001","unstructured":"Parra Salinas I, Bermudez A, L\u00f3pez Corral L, Lopez Godino O, M\u00f3les-Poveda P, Mart\u00edn G et al (2001) Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). Clin Transpl 35(5):e14255. https:\/\/doi.org\/10.1111\/ctr.14255","journal-title":"Clin Transpl"},{"issue":"19","key":"6604_CR32","doi-asserted-by":"publisher","first-page":"10411","DOI":"10.3390\/ijms251910411","volume":"25","author":"JT Nguyen","year":"2024","unstructured":"Nguyen JT, Jessri M, Costa-da-Silva AC, Sharma R, Mays JW, Treister NS (2024) Oral chronic Graft-Versus-Host disease: Pathogenesis, Diagnosis, current Treatment, and emerging therapies. Int J Mol Sci 25(19):10411. https:\/\/doi.org\/10.3390\/ijms251910411","journal-title":"Int J Mol Sci"},{"issue":"8","key":"6604_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","volume":"27","author":"DJ Martini","year":"2022","unstructured":"Martini DJ, Chen YB, DeFilipp Z (2022) Recent FDA approvals in the treatment of Graft-Versus-Host disease. Oncologist 27(8):685\u2013693. https:\/\/doi.org\/10.1093\/oncolo\/oyac076","journal-title":"Oncologist"},{"issue":"1","key":"6604_CR34","doi-asserted-by":"publisher","first-page":"e8501","DOI":"10.1038\/s41598-021-88080-3","volume":"11","author":"B Zhang","year":"2021","unstructured":"Zhang B, Chen L, Zhou J, Zu Y, Gui R, Li Z, Song Y (2021) Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia. Sci Rep 11(1):e8501. https:\/\/doi.org\/10.1038\/s41598-021-88080-3","journal-title":"Sci Rep"},{"issue":"5","key":"6604_CR35","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/j.bbmt.2020.01.012","volume":"26","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Huang H (2020) Calcineurin inhibitors replacement by ruxolitinib as Graft-versus-Host disease prophylaxis for patients after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 26(5):e128\u2013e133. https:\/\/doi.org\/10.1016\/j.bbmt.2020.01.012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"6604_CR36","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41409-022-01649-y","volume":"57","author":"RB Salit","year":"2022","unstructured":"Salit RB (2022) The role of JAK inhibitors in hematopoietic cell transplantation. Bone Marrow Transplant 57(6):857\u2013865. https:\/\/doi.org\/10.1038\/s41409-022-01649-y","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-025-06604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-025-06604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-025-06604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T08:48:22Z","timestamp":1763542102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00784-025-06604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":36,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6604"],"URL":"https:\/\/doi.org\/10.1007\/s00784-025-06604-x","relation":{},"ISSN":["1436-3771"],"issn-type":[{"type":"electronic","value":"1436-3771"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical Ethics Review Board of the University Medical Centre Groningen (No. M19.232532). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors of this brief article had no conflicts of interest. This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"552"}}